Anup Kasi1, Timothy McGinnis1, Gurudatta Naik2, Shivani Handa3, Grant Williams2, Ravi Paluri2. 1. Department of Medicine, Division of Medical Oncology, Kansas University Medical Center, Kansas City, KS, USA. 2. Department of Medicine, Division of Medical Oncology, University of Alabama at Birmingham, Birmingham, AL, USA. 3. Department of Internal Medicine, Icahn School of Medicine at Mount Sinai West & Morningside, NY, NY, USA.
Abstract
BACKGROUND: Nano-liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) is the regimen of choice in the 2nd line setting for advanced pancreatic adenocarcinoma (PAC). However, real-world data is limited. Our objectives were to elicit the real-word effectiveness and safety of this combination as an advanced line of therapy in pancreatic cancer patients and analyze the impact of prior lines of therapy on survival outcomes with this regimen. METHODS: We conducted a retrospective cohort study of 58 patients with locally advanced unresectable or metastatic PAC, who were treated with at least one dose of nal-IRI + 5-FU/LV following cancer progression on prior therapies between August 2015 and December 2018 at the Kansas University Medical Center (KUMC) and University of Alabama at Birmingham (UAB). RESULTS: Median OS was 5.4 (range, 4.2-7) months. Disease control rate (DCR) was highest (84%) for patients given nal-IRI + 5-FU/LV as 2nd line agent after progression on a 1st line gemcitabine-based regimen. However, no significant survival difference was observed between those given nal-IRI + 5-FU/LV after 1st line or beyond the 2nd line (P=0.17). Among those given nal-IRI + 5-FU/LV as 2nd line, use of gemcitabine-inclusive chemotherapy as the 1st line agent did not impact survival (P=0.68). Prior irinotecan exposure and baseline CA 19-9 level did not affect the overall survival (OS) but patients with a higher CA 19-9 level had a significant risk of progression (HR =3.2, P=0.02). Grade 3/4 toxicities were reported in only 19% patients. CONCLUSIONS: Our report suggests that nal-IRI + 5-FU/LV offers a modest survival benefit with a tolerable safety profile as an advanced line of treatment in patients with advanced PAC. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: Nano-liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) is the regimen of choice in the 2nd line setting for advanced pancreatic adenocarcinoma (PAC). However, real-world data is limited. Our objectives were to elicit the real-word effectiveness and safety of this combination as an advanced line of therapy in pancreatic cancer patients and analyze the impact of prior lines of therapy on survival outcomes with this regimen. METHODS: We conducted a retrospective cohort study of 58 patients with locally advanced unresectable or metastatic PAC, who were treated with at least one dose of nal-IRI + 5-FU/LV following cancer progression on prior therapies between August 2015 and December 2018 at the Kansas University Medical Center (KUMC) and University of Alabama at Birmingham (UAB). RESULTS: Median OS was 5.4 (range, 4.2-7) months. Disease control rate (DCR) was highest (84%) for patients given nal-IRI + 5-FU/LV as 2nd line agent after progression on a 1st line gemcitabine-based regimen. However, no significant survival difference was observed between those given nal-IRI + 5-FU/LV after 1st line or beyond the 2nd line (P=0.17). Among those given nal-IRI + 5-FU/LV as 2nd line, use of gemcitabine-inclusive chemotherapy as the 1st line agent did not impact survival (P=0.68). Prior irinotecan exposure and baseline CA 19-9 level did not affect the overall survival (OS) but patients with a higher CA 19-9 level had a significant risk of progression (HR =3.2, P=0.02). Grade 3/4 toxicities were reported in only 19% patients. CONCLUSIONS: Our report suggests that nal-IRI + 5-FU/LV offers a modest survival benefit with a tolerable safety profile as an advanced line of treatment in patients with advanced PAC. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
Entities:
Keywords:
2nd line treatment; Liposomal irinotecan; MM-398; nano-liposomal irinotecan (nal-IRI); pancreatic cancer
Authors: Andrea Wang-Gillam; Chung-Pin Li; György Bodoky; Andrew Dean; Yan-Shen Shan; Gayle Jameson; Teresa Macarulla; Kyung-Hun Lee; David Cunningham; Jean F Blanc; Richard A Hubner; Chang-Fang Chiu; Gilberto Schwartsmann; Jens T Siveke; Fadi Braiteh; Victor Moyo; Bruce Belanger; Navreet Dhindsa; Eliel Bayever; Daniel D Von Hoff; Li-Tzong Chen Journal: Lancet Date: 2015-11-29 Impact factor: 79.321
Authors: Helmut Oettle; Hanno Riess; Jens M Stieler; Gerhard Heil; Ingo Schwaner; Jörg Seraphin; Martin Görner; Matthias Mölle; Tim F Greten; Volker Lakner; Sven Bischoff; Marianne Sinn; Bernd Dörken; Uwe Pelzer Journal: J Clin Oncol Date: 2014-06-30 Impact factor: 44.544
Authors: Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar Journal: J Clin Oncol Date: 2007-04-23 Impact factor: 44.544
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Daryl C Drummond; Charles O Noble; Zexiong Guo; Keelung Hong; John W Park; Dmitri B Kirpotin Journal: Cancer Res Date: 2006-03-15 Impact factor: 12.701
Authors: Ibrahim Vedat Bayoglu; Umut Varol; Ibrahim Yildiz; Ugur Muslu; Ahmet Alacacioglu; Yuksel Kucukzeybek; Murat Akyol; Lutfiye Demir; Ahmet Dirican; Suna Cokmert; Yasar Yildiz; Bulent Karabulut; Ruchan Uslu; Mustafa Oktay Tarhan Journal: Asian Pac J Cancer Prev Date: 2014
Authors: Danielle C Glassman; Randze L Palmaira; Christina M Covington; Avni M Desai; Geoffrey Y Ku; Jia Li; James J Harding; Anna M Varghese; Eileen M O'Reilly; Kenneth H Yu Journal: BMC Cancer Date: 2018-06-27 Impact factor: 4.430